RE:Recommendation The problem with a stock that has a retail rather than institutional base is that no one keeps management honest; divide and conquer works really well. So once again I suggest an alternative.
Organize a shareholder group, pick a small number to represent the larger group and set up a meeting with management to discuss issues. At 5% of the float (roughly 10.2 million shares) a shareholder group would have significantly more leverage than individual shareholders - they could nominate directors, and propose resolutions at the AGM for instance.
This could be a mutually beneficial arrangement to open two way communication between management and a large number of shareholders. I personally believe that the more shareholders know the less likelihood of idle speculation.
For instance, while I would appreciate knowing when the company plans on updating shareholders on the FDA information request and the status of the phase 1 and 2 treated patients, it is even more important that all shareholders and future investors have that information as well. The only way the share price is going to rise is when more buyers come into the stock and fewer existing shareholders want to sell.
toade1313 wrote: All serious investors should call the company asking about the IND. Are we waiting for FDA response OR is FDA waiting for Theralase response.